Back to Search Start Over

Real-time imaging of mitochondrial redox reveals increased mitochondrial oxidative stress associated with amyloid ß aggregates in vivo in a mouse model of Alzheimer's disease

Authors :
Calvo-Rodriguez, Maria
Kharitonova, Elizabeth K.
Snyder, Austin C.
Hou, Steven S.
Sanchez-Mico, Maria Virtudes
Das, Sudeshna
Fan, Zhanyun
Shirani, Hamid
Nilsson, Peter
Serrano-Pozo, Alberto
Bacskai, Brian J.
Calvo-Rodriguez, Maria
Kharitonova, Elizabeth K.
Snyder, Austin C.
Hou, Steven S.
Sanchez-Mico, Maria Virtudes
Das, Sudeshna
Fan, Zhanyun
Shirani, Hamid
Nilsson, Peter
Serrano-Pozo, Alberto
Bacskai, Brian J.
Publication Year :
2024

Abstract

BackgroundReactive oxidative stress is a critical player in the amyloid beta (A beta) toxicity that contributes to neurodegeneration in Alzheimer's disease (AD). Damaged mitochondria are one of the main sources of reactive oxygen species and accumulate in A beta plaque-associated dystrophic neurites in the AD brain. Although A beta causes neuronal mitochondria reactive oxidative stress in vitro, this has never been directly observed in vivo in the living mouse brain. Here, we tested for the first time whether A beta plaques and soluble A beta oligomers induce mitochondrial oxidative stress in surrounding neurons in vivo, and whether this neurotoxic effect can be abrogated using mitochondrial-targeted antioxidants.MethodsWe expressed a genetically encoded fluorescent ratiometric mitochondria-targeted reporter of oxidative stress in mouse models of the disease and performed intravital multiphoton microscopy of neuronal mitochondria and A beta plaques.ResultsFor the first time, we demonstrated by direct observation in the living mouse brain exacerbated mitochondrial oxidative stress in neurons after both A beta plaque deposition and direct application of soluble oligomeric A beta onto the brain, and determined the most likely pathological sequence of events leading to oxidative stress in vivo. Oxidative stress could be inhibited by both blocking calcium influx into mitochondria and treating with the mitochondria-targeted antioxidant SS31. Remarkably, the latter ameliorated plaque-associated dystrophic neurites without impacting A beta plaque burden.ConclusionsConsidering these results, combination of mitochondria-targeted compounds with other anti-amyloid beta or anti-tau therapies hold promise as neuroprotective drugs for the prevention and/or treatment of AD.<br />Funding Agencies|National Institute on Aging; Schepens Eye Research Institute Gene Transfer Vector Core

Details

Database :
OAIster
Notes :
English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1442969917
Document Type :
Electronic Resource
Full Text :
https://doi.org/10.1186.s13024-024-00702-2